Voices to Trials: Engaging Patients in Clinical Trial Design
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho
AstraZeneca inks $2bn Treg cell therapy deal with Quell
UK startup Quell Therapeutics has secured a partnership with AstraZeneca focused on cell therapies for autoimmune diseases that comes with $85 million upfront payment and
One size does not fit all: Why a shift is needed in how we t...
Two of the biggest advances in healthcare in the last decade have been the gradual de-stigmatisation of mental health and the increased interest in researching the causes and treatments of
Epistemic AI launches biomedical GPT at BIO
One of the most compelling things about artificial intelligence chat technologies like ChatGPT and AIChat is their ability to generate human-like responses - but that may
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
3rd Rare & Genetic Kidney Disease Drug Development Summit
With the pivotal acceptance of eGFR as a surrogate endpoint along with the advances in genetic therapies and disease pathology sequencing, the floodgates for faster approval and developments in pre
3rd Annual iPSC Derived-Cell Therapies Summit
As the iPSC space continues to evolve and candidates move to the clinic, the need to unite with your peers to benchmark the current bottlenecks in discovery, translation and clinical strategy is gr
3rd Annual Tumor-Myeloid-Directed Therapies Summit
The role of the myeloid compartment in tumor resistance is becoming clear.
Gene Therapy Potency Assay Summit
The Inaugural Gene Therapy Potency Summit (August 29-31) is dedicated to providing you with tools to identify, characterize and measure potency, enabling you to take tactical insights back
mRNA Cancer Vaccine Summit 2023
The mRNA Cancer Vaccine Summit 2023 comes to Boston as the community is on the cusp of something truly exciting.